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ABSTRACT:  
Objective: Little is known about the evolution of programme outcomes 
associated with rapid expansion of ART in resource-limited settings.  We 
describe temporal trends and assess associations with mortality and loss to 
follow-up (LTFU) in HIV cohorts from 8 countries.  
Design: Multi-cohort study using electronic health records. 
Methods: Analysis included adults in twenty-five Médecins Sans Frontières 
supported programmes initiating ART between 2001 and 2011.  Kaplan-Meier 
methods were used to describe time to death or LTFU, and proportional hazards 
models to assess associations with individual and programme factors.  
Results: ART initiation (n=132 334; median age 35 years; 61% female) 
expanded rapidly. While 36-month mortality decreased from 22% to 9% over 5 
years (≤2003-2008), LTFU increased from 11% to 21%. Hazard ratios (HR) of 
early (0-12 months) and late (12-72 months) LTFU increased over time, from 
1.09 (95%CI 0.83-1.43) and 1.04 (95%CI 0.84-1.28) in 2004, to 3.29 (95%CI 
2.42-4.46) and 6.86 (95%CI 4.94-9.53) in 2011, compared to 2001-2003. Rate of 
programme expansion was strongly associated with increased early and late 
LTFU, adjusted HR (aHR)=2.31 (95%CI 1.78-3.01) and HR=2.29 (95%CI 1.76-
2.99), respectively, for ≥125 vs. 0-24 patients/month.  Larger programme size 
was associated with decreased early mortality (aHR=0.49, 95%CI 0.31-0.77 for 
≥20 000 vs. <500 patients), and increased early LTFU (aHR=1.77, 95%CI 1.04-
3.04 for ≥20 000 vs. <500 patients). 
Conclusion: As ART expands in resource-limited settings, challenges remain in 
improving access to ART and preventing programme attrition.  There is an 
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urgent need for novel and sustainable models of care to increase long-term 
retention of patients.   
 
 
Keywords: Antiretroviral therapy (highly active);  loss to follow-up;  mortality;  
programme outcomes;  retention;  survival analysis 
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INTRODUCTION 
Over the past decade, there has been rapid expansion of antiretroviral therapy 
(ART) in resource-limited settings.  By 2011, an estimated 9.7 million people in 
low- and middle-income countries were receiving ART[1].  During this growth, 
HIV programmes have adapted services to cope with the increasing numbers of 
patients requiring ART. As programmes mature and increase in size, the need to 
ensure long-term retention in care of patients receiving ART while continuing 
timely initiation of new patients onto treatment presents an ongoing challenge to 
policy makers and health care providers alike.   
 
Over the past decade, the conditions in which ART programmes operate in low 
and middle-income countries have changed considerably.  The numbers of 
patients has increased rapidly and often disproportionately to the number of 
health care workers providing care[2]. Guidelines for initiation of ART have been 
simplified and context specific recommendations have been adapted to facilitate 
improving and expanding access to treatment.  Furthermore, eligibility criteria 
for ART initiation have evolved and recommended CD4 count thresholds for 
treatment start have recently been increased to improve patient outcomes[3]. 
 
The effectiveness of ART in reducing morbidity and mortality depends on patient 
adherence to therapy and on the ability of HIV programmes to retain patients in 
care.  Previous analyses examining temporal trends in long-term programme 
outcomes in resource-limited settings have reported conflicting results.  While 
data from South Africa showed increasing loss to follow-up (LTFU) by calendar 
year of enrolment [4-6]; systematic reviews of sub-Saharan African cohorts and 
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findings from a large Kenyan cohort reported improvements in patient retention 
in recent years [7-9].  Evaluating programme outcomes, assessing temporal 
trends in programme retention and investigating the factors associated with 
poor outcomes are essential to improve the long-term effectiveness of ART 
services in low and middle-income countries.  Understanding associations 
between programme expansion and treatment outcomes are particularly 
relevant in the context of the Treatment 2.0 initiative to scale up HIV treatment 
through promoting innovation and efficiency gains, and of the ambitious goal of 
expanding ART to 15 million people by 2015[1, 10]. 
 
The objective of this study was to describe temporal trends in patient 
characteristics at ART initiation and in ART outcomes using data from resource-
limited countries where Médecins Sans Frontières (MSF) supports the provision 
of HIV treatment. We also examined associations between individual level risk 
factors, absolute programme size, and rate of ART programme expansion, and 
mortality and loss to follow-up (LTFU). 
 
METHODS 
Study population 
We analysed patient electronic health records from 25 sites in 8 countries where 
MSF supports the provision of ART care.  Cohorts were located in Democratic 
Republic of Congo (DRC), India, Kenya, Malawi, Mozambique, Myanmar, Uganda 
and Zimbabwe. Details of these programmes have been described 
previously[11].  All programmes provided care and treatment free of charge. 
Criteria for ART initiation followed WHO guidelines.  The analysis included all 
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adults aged 16 years or older who initiated ART between March 2001 and 
September 2011 in one of the programmes.   
 
Data collection and definitions 
Characteristics at ART initiation including sex, age, CD4 cell counts, WHO clinical 
stage, body mass index (BMI), and date of ART initiation, were prospectively 
collected with the FUCHIA software (Epicentre, Paris).   Throughout, reference to 
baseline is a reference to time of ART initiation.    
 
Patient follow-up began at the date of ART initiation and was censored at the 
earliest of: death, transfer out, last clinic visit, or analysis closure.  Sites began 
initiating patients onto ART between 2001 and 2007. Only patients with a 
minimum of 6-months of follow-up were included with analysis closure 
preceding the database closure date by 6-months. The database closure ranged 
from 30 September 2011 to 20 March 2012.  Deaths were events recorded 
before the analysis closure date. Loss to follow-up was defined as having no visit 
in the 6-months before analysis closure. Patients who initiated treatment but did 
not return were given 1-day of follow-up time so that they would contribute to 
survival analysis[12]. Programme retention was defined as being in care (i.e., not 
dead or LTFU) at the time of analysis closure.     
 
To quantify the size of the ART programmes two variables, programme size and 
the rate of programme expansion, were defined.  For each patient, programme 
size was calculated as the total number of both pre-ART and ART patients 
receiving care in the programme at the end of the calendar year of patient ART 
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initiation. To define the rate of programme expansion, the rank of each patient 
enrolled by site was divided by the duration of ART provision in the site up to the 
date of enrolment, in months.   For example, if the one hundredth patient at the 
site was enrolled 4 months after the programme started, the rate of programme 
expansion for that patient would be 25 (100/4).  
 
Statistical methods 
Baseline characteristics were described by year of ART initiation using medians 
and interquartile ranges for continuous variables, and proportions for 
categorical variables.  Kaplan-Meier methods were used to describe cumulative 
probabilities of death, LTFU and programme retention after ART initiation and 
were analysed overall, by calendar year of ART start, programme size, and rate of 
expansion. 
 
Cox’s proportional hazards models were used to assess associations between 
baseline patient characteristics and outcomes. Heterogeneity across sites was 
accounted for using random effects.  To examine differences in risk factors over 
time, models were stratified by early (0-12 months) and late (12-72 months) 
follow-up time periods.  Adjusted models were built first by including all 
baseline characteristics (model 1), and then adding the programme size variable 
(model 2), or the rate of expansion variable (model 3), or both (model 4).  The 
primary analysis only included patients with complete data on baseline 
characteristics (complete case analysis).   
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In sensitivity analyses, models including patients with missing baseline CD4 cell 
counts, clinical stage, and/or BMI as separate categories were used. We also 
assessed different measures of programme size including the number of patients 
who had previously initiated ART by site and the number of ART patients in care 
at each site at the end of the calendar year. Kaplan-Meier survival proportions 
and hazard ratios (HRs) stratified by site were assessed and compared with the 
primary results. Finally, to account for non-differential censoring (e.g. higher risk 
of death among patients LFTU early after ART start), models of time to death and 
LTFU were calculated using competing risks methods[13].     
 
Data was analysed with STATA 12.0 (STATA Corporation, College Station, Texas, 
USA). All FUCHIA sites obtained agreement from health ministries for the 
prospective collection of data.  No patient identifiers were included in datasets.  
The International Ethics Review Board of MSF reviewed the study and 
determined it did not require formal approval.  The Human Subjects Research 
Ethics Committee of the Faculty of Health Sciences from the University of Cape 
Town reviewed and approved the data usage and analysis plan. 
 
RESULTS 
Characteristics at ART initiation 
Between 2001 and 2011, 132 334 individuals contributed 299 658 person-years 
of follow-up (median per patient, 1.75 years, interquartile range (IQR), 0.57-
3.56).  At ART initiation, the median age was 35 years, 61% of patients were 
female, 69% had CD4 cell counts <200 cells/µL and less than 5% had CD4 count 
>350 cells/µL (Table 1).  Twenty-five percent of patients had clinical stage 4 
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disease and a third had a BMI below 18.5 kg/m2. More than half of patients 
received treatment in Malawi (n=37 657) or Zimbabwe (n=30 783); Asian 
cohorts contributed 14% of patients.    
 
Temporal changes in patient baseline characteristics and outcomes 
The number of patients initiating ART increased substantially each calendar year 
(Table 2), from 4 427 in 2001-2003 to 22 863 in 2010.  Median age was 35 years 
and remained constant over time.  Median CD4 cell count increased over time 
from 97 in 2003 or earlier to 184 cells/µL in 2011 (see Web Appendix 1, 
Supplemental Digital Content, http://links.lww.com/QAI/A547).  However, 
every year approximately 30% of patients initiated ART with a CD4 count <100 
cells/µL (see Web Appendix 2, Supplemental Digital Content, 
http://links.lww.com/QAI/A547); the range across countries being 22-48%.  
The proportion of patients with clinical stage 4 disease at the time of ART 
initiation decreased from 44% to 14%.  
 
Mortality decreased over the study period (Figure 1A), from 17% to 5% at 12 
months; and from 22% to 9% at 36 months (Table 3). Larger programmes 
(Figure 1C) and those with greater rate of expansion (Figure 1D) had lower rates 
of mortality.  In contrast, LTFU increased substantially over time, from 6% to 
15% at 12 months; and from 11% to 21% at 36 months (Figure 1B).  LTFU 
increased with programme size up to a number of 7 500 patients (Figure 1D). 
Programme retention was highest between 2006 and 2009. Trends in outcomes 
were homogeneous across sites (see Web Appendix 3, Supplemental Digital 
Content, http://links.lww.com/QAI/A547).  
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The contribution of LTFU to overall programme attrition increased with 
duration of ART (see Web Appendix 4, Supplemental Digital Content, 
http://links.lww.com/QAI/A547).  During the first year of treatment, 
approximately half of the programme losses were LTFU (6% of patients had died 
compared to 8% who were LTFU). However, after five years, two thirds of the 
losses were LTFU patients (24% compared to 13% of deaths).  Programme 
retention decreased from 82% at 12 months, to 73% at 36 months and 66% at 
60 months.  The smallest programmes had the largest estimates of 12-month 
mortality: 12%, 11% and 9% in sites with less than 500, 500-999 and 1 000-2 
499 people, respectively.  However, 12 month LTFU was largest in medium size 
programs.  Similarly, programmes with a slow rate of expansion had double the 
risk of 12-month mortality compared those with fastest expansion (10.0% vs. 
5.3%).  LTFU was lowest in programmes with a slow rate of expansion compared 
to those with medium or fast expansion (Figure 1F).   
 
Risk factors for mortality 
The risk of death decreased with each successive calendar year of enrolment 
(Table 3).  After adjusting for programme size and rate of expansion this 
association was only seen for the 0-12 month period and up to 2007 (aHR=0.76, 
95%CI 0.61-0.95 for 2007; and aHR=1.00, 95% CI 0.76-1.33, for 0-12 months, 
and aHR=1.21, 95% CI 0.73-2.00, for 12-72 months, vs. ≤2003). 
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Larger programme size was associated with decreased early mortality 
(aHR=0.49, 95% CI 0.31-0.77, for ≥20 000 vs. <500 patients). This association 
was not significant for late mortality (aHR=0.34, 95% CI 0.09-1.27). 
Fully adjusted models did not show evidence of association between rate of 
expansion and early or late mortality (aHR=1.13, 95%CI 0.87-1.48, and 
aHR=0.85, 95%CI 0.55-1.31, respectively, for ≥125 vs. <25 patients/month). 
Increased early and late mortality was associated with male gender (aHR=1.30, 
and 1.57, respectively), older age (aHR=1.46, and 1.48, respectively, for ≥45 vs. 
16-25 years), and low BMI (aHR=2.59, and 1.56, respectively, for ≤18.5 vs. 18.6-
25.0 kg/m2). Death was also strongly associated with advanced clinical stage and 
lower CD4 count level, with the strongest associations observed with early 
mortality (aHR=2.65 for stage 4 vs. stages 1 or 2; and aHR=0.29, 0.26-0.32 for 
200-349 vs. <25 CD4 cells/µL).  
 
Risk factors for lost to follow-up 
Increased risk of early and late LTFU was observed with each successive 
calendar year of ART initiation (Table 4).  Adjusted hazard ratios for early LFTU 
increased from 1.09 (95%CI 0.83-1.43) in 2004 to 3.29 (95%CI 2.42-4.46) in 
2011, compared to the 2001-2003 period; and adjusted hazard ratio for late 
LTFU from 1.04 (95%CI 0.84-1.28) to 6.86 (95%CI 4.94-9.53), respectively. 
Larger programme size was associated with a 7-fold increase in the risk of early  
(HR 7.35, 95% CI 5.55-9.73) and late LTFU (HR 7.03, 95% CI 4.30-11.48) but the 
association in final models attenuated for early LTFU (aHR 1.77, 95% CI 1.04-
3.04) and was not observed for late LTFU (aHR 0.53, 95% CI 0.27-1.04).   Rate of 
programme expansion was strongly associated with an increased risk of early 
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and late LTFU (early aHR increased from 1.26 in programmes with rates of 25-
59 patients/month to 2.31 in those with ≥125 patients/month; and late aHR 
from 1.22 to 2.29 compared to programmes with rates of 0-24 patients/month 
respectively).  Late LTFU was only higher among patients who received 
treatment in programmes with 500-4999 HIV patients in care (aHR=1.34, 95%CI 
1.00-1.80 for 2500-4999 vs. <500 programme size).  
 
Male gender (aHR=1.25 and 1.21, for early and late periods), younger age 
(aHR=0.58 and 0.48, respectively, for ≥45 vs. 16-25 years) and advanced clinical 
stage (aHR=1.56 and 1.28, respectively, for stage 4 vs. stages 1 or 2) were also 
associated with an increased risk of LTFU.  Patients with a CD4 cell count of less 
than 25 cells/µL had a higher risk of early LTFU (adjusted hazard ratio 
decreased from 0.89 among patients with 25-49 cells/µL to 0.60 among those 
with 200-349 cells/µL). No association between CD4 cell count and late LTFU 
was observed.    
 
Sensitivity analyses including patients with missing data (see Web Appendix 5 
and 6, Supplemental Digital Content, http://links.lww.com/QAI/A547) and 
stratification by site provided similar results.  Estimates from competing risks 
models were slightly reduced but did not change results (see Web Appendix 7 
and 8, Supplemental Digital Content, http://links.lww.com/QAI/A547).    
 
DISCUSSION 
This multicentre cohort study included over 130 000 HIV-infected patients 
initiated on ART in 8 low and middle-income countries where the provision of 
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ART has rapidly expanded over the last 10-years.  In this challenging context 
where programmes needed to adapt to the growing numbers of patients in need 
for care, we observed a gradual improvement in measures of disease severity at 
ART initiation and a decrease in mortality over time.  Despite this finding, every 
year 30% of the total number of patients who initiated ART had CD4 cell counts 
less than 100 cells/µL.  Furthermore, twelve, 24 and 36-month LTFU rates 
among patients initiating ART in successive calendar years doubled between the 
periods 2001-2003 and 2008.  
 
Over the 10-year study period, ART provision was rapidly implemented and 
programmes expanded to reach a growing number of people infected with HIV.   
Expansion rates ranged from 0-25 to 125-192 new patients/month, and 
programme size from <500 to 20 000-23 995 patients.  Mortality gradually 
improved with 6-month estimates decreasing from 14% in the years before 2004 
to less than 4% in 2011, which is consistent with reports from South Africa[14].  
The observed decreased estimates of mortality may result from improved access 
to ART, as suggested by the increased number of patients initiating ART with less 
severe disease.  The rapid growth of programmes might have also led to poorer 
outcome ascertainment, with greater number of deaths occurring in recent years 
misclassified as LTFU[15].  Linkage to national death registries is not available in 
these cohorts highlighting the need to improve outcome ascertainment for 
programme evaluation in resource-limited countries.  
 
The rapid growth of ART programmes is related to a combination of several 
factors including the long-term availability of antiretroviral drugs, the 
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implementation of new simplified guidelines for ART, and the widespread 
availability of CD4 enumeration to identify ART-eligible individuals. A third of 
patients initiated ART with a CD4 cell count below 100, placing a substantial 
strain on the health-care system requiring intensive support from clinically 
trained staff [16, 17].  Our findings do not suggest that increases in treatment 
guideline thresholds prevent patients with more advanced HIV disease from 
accessing care, but rather that all programmes still face challenges in timeously 
seeking, testing, and linking patients to ART care.   
 
Even with continued challenges to improving access to ART, LTFU appears to 
present a ubiquitous challenge to the long-term effectiveness of ART 
programmes.  After 2-years of ART, 15% of the cohort was LTFU and retention 
was 77% and after 5-years of treatment two-thirds of patients remained in care.  
This is slightly less than the estimate from 23 countries with cohorts of more 
than 2000 people which reported 72% retention after 5-years[1].  A temporal 
trend of increasing LTFU was observed with LTFU contributing an increasing 
proportion of overall programme attrition[14, 18].  These findings confirm the 
urgent need to refocus efforts to improve long-term retention and contradict 
systematic reviews from sub-Saharan Africa suggesting that programme 
outcomes are improving[7, 18].  A novel finding of our study is that the rate of 
programme expansion, more than the size of the HIV programme, was associated 
with the high levels of LTFU. This is likely to relate to the need for timely 
adjustments in programmes to cope with the increase in activity, independently 
of financial and human resource allocation.  Associations observed between 
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LTFU and male gender, younger age, and advanced clinical stage are consistent 
with previous reports[14, 19-21].   
 
This analysis of long-term outcomes was based on substantial follow-up of a 
large number of patients treated in several resource-limited ART programmes.  
All sites offered care and treatment free of charge, followed WHO 
recommendations for ART initiation, and site heterogeneity was accounted for 
using random effects in the Cox’s models.  These data are not likely to be 
representative of all ART programmes since MSF provides additional resources 
and technical support.  For example, quality and completeness of routine 
electronic data are challenging but MSF provides considerable means to address 
these concerns[2].  Without linkage to death registries, estimates of programme 
attrition may misclassify some proportion of deaths as losses to follow-up[5, 15, 
19, 22, 23]. LTFU may be overestimated further due to administrative errors, 
incomplete records of patient decentralization and unrecorded transfers and the 
contribution of treatment interrupters [2, 21, 24-26].  Furthermore, we were 
unable to minimize this bias as we did not have data on tracing for all or a 
sample of those who were LTFU[27]. Our focus was limited to programme 
outcomes after ART acknowledging that a substantial proportion of patients 
were lost during pre-ART care[28-31].  While programme size and the rate of 
expansion were adjusted for, residual confounding may be present if important 
internal organisational aspects were not sufficiently captured and from 
unmeasured factors.  Sensitivity analyses confirmed our results investigating 
differences by programme, including patients with missing covariate data, and 
adjusting for site heterogeneity. A competing risks approach led to very similar 
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findings corroborating that the traditional Cox’s proportional hazards models 
are appropriate[32, 33].  
 
Our findings explore the tension and challenges involved in pursuing the 
ambitious goals of expanding ART to 15 million people by 2015 and 
implementing “Treatment 2.0” strategies in high prevalence, resource-limited 
settings[1, 10].  Recent Treatment as Prevention models assumed a long-term 
drop-out rate of 1.5% annually, which appears optimistic considering our 
estimates of long-term retention[34].   With a high burden of acutely ill patients, 
ART programmes will struggle to expand access to patients in earlier stages of 
HIV disease without additional resources.  With new 2013 WHO guidelines to 
expand ART access to an additional 9.2 million people in low- and middle-
income countries, we need to fully understand the individual and programmatic 
implications of earlier initiation[1].  
 
Over a decade, ART programmes have expanded in high prevalence, resource-
limited settings with a focus to increase access to care and thus patient numbers.  
Today, many sites hold high numbers of HIV-infected patients, above 20,000 at 
some sites. The quality of ART services and psychosocial counselling at these 
large sites may be taking a back seat as the drive for expansion continues.  The 
conscious trade-off between numbers and quality deserves more discussion and 
close monitoring as the targets for expansion of treatment continue to increase. 
The findings of our study suggest that, potentially, ART sites should be capped at 
a maximum number of patients and the rate of enrolment restricted in favour of 
balancing growth with quality care. Site human resource capacity and 
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programme organisation characteristics are likely to be important determinants 
to consider in achieving this balance and deserve further investigation to provide 
effective recommendations regarding maximum patient volume and expansion 
rate at programme level.  
 
For the first time, the WHO guidelines acknowledge the challenge of long-term 
retention in ART programmes with explicit guidance on operations and service 
delivery, including adherence, retention, decentralization and task shifting[3].  
Additional resources are needed to strengthen monitoring systems to ascertain 
true outcomes of children and adults lost to care pre- and post-ART initiation[15, 
35]. Identification of ART patients disengaged from care is critical as they are at 
an increased risk of developing and transmitting drug resistant strains of 
HIV[18].  There is an urgent need to determine sustainable and optimal models 
of care for stable patients on lifelong ART, especially in large programmes in 
high-prevalence, resource-limited settings.  Decreasing visit frequency by 
expanding intervals between prescription refills, decentralizing ART delivery 
into community-based patient led groups, and introducing flexible systems to 
support mobile populations are all interventions that could be considered and 
assessed on a large-scale[36-39].   
 
In summary, ART programmes in resource-limited settings have grown rapidly 
over the last decade.  However, significant work remains to continue expanding 
access while addressing the growing challenge of programme attrition.  
Sustainable models of care for long-term retention of patients in large, high-
prevalence, resource-limited settings are urgently needed.  
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Figure Legends:  
 
Figure 1. Cumulative probability of death and LTFU stratified by year of ART 
initiation, programme size, or rate of expansion 
A) Mortality by year of ART initiation 
B) LTFU by year of ART initiation 
C) Mortality by programme size 
D) LTFU by programme size 
E) Mortality by rate of expansion 
F) LTFU by rate of expansion 
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Table 1: Patient characteristics at ART initiation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IQR, interquartile range 
 
 
Characteristics 
No. of patients 
N=132 334 
Sex, n (%)  
Females 80 456 (60.8) 
Age (years)  
Median [IQR] 35.0 [29.4-42.0] 
Age group, n (%)  
16-25 11 840 (9.0) 
25-34 53 332 (40.3) 
35-44 42 894 (32.4) 
45+ 24 268 (18.3) 
CD4 cell count (cell/µ/L) n=103 197 (78.0) 
Median [IQR] 142 [63-220] 
Level, n (%)  
<25 10 890 (10.6) 
25-49 10 054 (9.7) 
50-99 16 826 (16.3) 
100-149 16 220 (15.7) 
150-199 17 253 (16.7) 
200-349 27 484 (26.6) 
≥350 4 470 (4.3) 
Clinical stage, n(%) n=129 859 (98.1) 
1 & 2 41 105 (31.7) 
3 56 619 (43.6) 
4 32 135 (24.8) 
BMI group (kg/m2), n (%) n=121 809 (92.0) 
Underweight (≤18.5) 40 122 (32.9) 
Normal (18.6-25.0) 72 217 (59.3) 
Overweight (25.1-30.0) 7 727 (6.4) 
Obese (>30.0) 1 733 (1.4) 
Country, n (%)  
DRC 4 140 (3.1) 
India 1 526 (1.2) 
Kenya 19 353 (14.6) 
Malawi 37 657 (28.5) 
Mozambique 12 492 (9.4) 
Myanmar 16 784 (12.7) 
Uganda 9 599 (7.3) 
Zimbabwe 30 783 (23.3) 
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Table 2: Baseline characteristics and 6-, 12- and 36-month Kaplan-Meier cumulative mortality, loss to follow-up and overall 
programme retention stratified by calendar year of ART initiation 
 Year of ART initiation 
 ≤2003 
n=4 427 
2004 
n=8 410 
2005 
n=10 974 
2006 
n=15 383 
2007 
n=19 826 
2008 
n=18 991 
2009 
n=19 410 
2010 
n=22 863 
2011 
n= 12 050 
Age (years), median [IQR] 34.7 [29.4-41.1] 35.1 [29.4-42.1] 35.0 [29.5-41.9] 34.9 [29.4-41.8] 35.0 [29.8-42.1] 35.1 [29.4-42.1] 35.1 [29.3-42.0] 35.0 [29.3-42.0] 35.0 [29.4-42.0] 
CD4 cell count  
(cell/µ/L), median [IQR] 
97 [42-162] 114 [51-178] 116 [50-182] 112 [48-189] 132 [58-205] 150 [72-221] 155 [74-224] 171 [80-248] 184 [77-276] 
Clinical stage 4, n(%)  1 914 (44.4) 3 659 (44.3) 4 276 (40.3) 5 254 (35.0) 5 266 (27.0) 3 814 (20.7) 3 253 (17.0) 3 030 (13.4) 1 669 (14.0) 
Underweight, n(%) 1 567 (38.9) 2 672 (27.9) 3 744 (38.5) 5 470 (38 2) 6 254 (33.3) 5 594 (31.5) 5 703 (31.3) 5 785 (27.7) 3 333 (30.1) 
Cumulative mortality,  
(95% CI) 
         
6-month 14.1 (13.1-15.2) 9.3 (8.7-9.9) 8.1 (7.6-8.6) 8.0 (7.6-8.5) 5.4 (5.1-5.7) 5.2 (4.9-5.5) 4.5 (4.2-4.8) 4.1 (3.8-4.3) 3.7 (3.3-4.2) 
12-month 17.3 (16.2-18.5) 11.8 (11.1-12.6) 10.2 (0.6-10.8) 9.9 (9.4-10.4) 6.8 (6.4-7.2) 6.5 (6.1-6.9) 5.6 (5.2-5.9) 5.1 (4.8-5.4) - 
36-month 21.5 (20.3-22.8) 15.4 (14.6-16.3) 13.7 (13.0-14.4) 12.8 (12.2-13.3) 9.5 (9.1-10.0) 8.8 (8.4-9.2) - - - 
Cumulative LTFU,  
(95% CI) 
         
6-month 4.0 (3.4-4.6) 6.9 (6.4-7.5) 6.2 (5.8-6.7) 5.9 (5.5-6.3) 7.6 (7.2-8.0) 8.4 (8.0-8.8) 7.3 (7.0-7.7) 9.2 (8.8-9.6) 11.3 (10.4-12.2) 
12-month 5.9 (5.2-6.7) 9.3 (8.7-9.9) 8.9 (8.4-9.5) 8.1 (7.7-8.5) 10.3 (9.8-10.7) 11.5 (11.0-11.9) 10.3 (9.9-10.7) 14.6 (14.1-15.2) - 
36-month 11.4 (10.4-12.5) 16.3 (15.5-17.2) 14.6 (13.9-15.3) 14.6 (14.0-15.2) 17.1 (16.6-17.7) 21.2 (20.5-21.8) - - - 
Cumulative programme  
retention in care, (95% CI) 
         
6-month 82.4 (81.3-83.5) 84.5 (83.7-85.2) 86.2 (85.6-86.9) 86.6 (86.0-87.1) 87.4 (87.0-87.9) 86.8 (86.3-87.3) 88.5 (88.1-89.0) 87.1 (87.7-87.6) 85.5 (84.5-86.4) 
12-month 77.8 (76.6-79.0) 80.0 (79.1-80.8) 81.8 (81.1-82.5) 82.8 (82.2-83.4) 83.6 (83.1-84.2) 82.8 (82.2-83.3) 84.7 (84.2-85.2) 81.0 (80.5-81.6) - 
36-month 69.6 (68.2-70.9) 70.8 (69.8-71.7) 73.8 (72.9-74.6) 74.5 (73.8-75.2) 75.0 (74.4-75.6) 71.9 (71.2-72.6) - -  
CI, confidence interval; IQR, interquartile range; LTFU, lost to follow-up. 
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Table 3: Cox proportional hazards estimates of mortality by baseline characteristics and year of ART initiation, adjusted by cohort. * 
 0-12 months 12-72 months 
 Univariate 
 
HR (95% CI) 
Model 1 
(n=94 571) 
HR (95% CI) 
Model 2 
(n=94 571) 
HR (95% CI) 
Model 3 
(n=94 571) 
HR (95% CI) 
Model 4 
(n=94 571) 
HR (95% CI) 
Univariate 
 
HR (95% CI) 
Model 1 
(n=62 080) 
HR (95% CI) 
Model 2 
(n=62 080) 
HR (95% CI) 
Model 3 
(n=62 080) 
HR (95% CI) 
Model 4 
(n=62 080) 
HR (95% CI) 
Year of ART initiation           
≤2003 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
2004 0.67 (0.61-0.74) 0.67 (0.58-0.78) 0.74 (0.62-0.88) 0.75 (0.64-0.87) 0.78 (0.65-0.94) 0.77 (0.66-0.91) 0.78 (0.63-0.97) 0.85 (0.66-1.09) 0.88 (0.70-1.10) 0.87 (0.68-1.13) 
2005 0.53 (0.48-0.58) 0.62 (0.54-0.71) 0.77 (0.64-0.94) 0.75 (0.64-0.88) 0.82 (0.65-0.94) 0.69 (0.59-0.81) 0.72 (0.58-0.88) 0.84 (0.64-1.11) 0.82 (0.65-1.04) 0.85 (0.64-1.11) 
2006 0.51 (0.47-0.56) 0.61 (0.54-0.69) 0.77 (0.64-0.93) 0.76 (0.65-0.89) 0.80 (0.66-0.97) 0.58 (0.50-0.68) 0.63 (0.52-0.77) 0.75 (0.57-0.98) 0.74 (0.58-0.94) 0.75 (0.57-0.99) 
2007 0.36 (0.33-0.40) 0.47 (0.42-0.53) 0.71 (0.57-0.88) 0.60 (0.51-0.71) 0.76 (0.61-0.95) 0.53 (0.46-0.62) 0.64 (0.53-0.78 0.75 (0.55-1.03) 0.76 (0.59-0.98) 0.76 (0.55-1.04) 
2008 0.34 (0.31-0.38) 0.55 (0.48-0.62) 0.85 (0.68-1.07)  0.72 (0.60-0.86) 0.91 (0.72-1.14) 0.46 (0.38-0.54) 0.58 (0.47-0.72) 0.69 (0.49-0.97) 0.71 (0.53-0.99) 0.72 (0.51-1.01) 
2009 0.29 (0.26-0.32) 0.54 (0.48-0.61) 0.94 (0.74-1.19)  0.71 (0.59-0.85) 0.98 (0.77-1.26) 0.43 (0.35-0.52) 0.60 (0.47-0.76) 0.73 (0.50-1.06) 0.72 (0.53-0.99) 0.74 (0.51-1.08) 
2010 0.27 (0.24-0.29) 0.58 (0.51-0.65) 0.95 (0.74-1.21) 0.76 (0.63-0.91) 1.00 (0.78-1.29) 0.50 (0.35-0.72) 0.83 (0.56-1.23) 1.19 (0.72-1.96) 1.01 (0.65-1.56) 1.21 (0.73-2.00) 
2011 0.28 (0.24-0.32) 0.60 (0.50-0.71) 0.95 (0.72-1.25) 0.78 (0.63-0.97) 1.00 (0.76-1.33) - - - - - 
Programme size (patients)          
<500 1.0 (ref)  1.0 (ref)  1.0 (ref) 1.0 (ref)  1.0 (ref)  1.0 (ref) 
500-999 0.90 (0.79-1.03)  1.19 (0.98-1.45)  1.15 (0.94-1.40) 0.83 (0.69-1.00)  0.99 (0.77-1.27)  0.99 (0.77-1.27) 
1000-2499 0.64 (0.57-0.72)  1.17 (0.95-1.42)  1.14 (0.94-1.40) 0.77 (0.65-0.91)  1.07 (0.83-1.39)  1.08 (0.83-1.40) 
2500-4999 0.51 (0.45-0.57)  0.99 (0.78-1.24)  0.97 (0.77-1.24) 0.59 (0.49-0.71)  0.84 (0.62-1.14)  0.87 (0.63-1.21) 
5000-7499 0.31 (0.27-0.35)  0.65 (0.49-0.86)  0.61 (0.45-0.82) 0.42 (0.34-0.52)  0.75 (0.51-1.11)  0.76 (0.50-1.16) 
7500 – 9999 0.26 (0.23-0.30)  0.57 (0.42-0.76)  0.48 (0.34-0.68) 0.38 (0.29-0.51)  0.70 (0.44-1.10)  0.72 (0.42-1.22) 
10000-14999 0.22 (0.19-0.25)  0.75 (0.54-1.03)  0.61 (0.41-0.90)  0.42 (0.33-0.54)  0.95 (0.59-1.53)  1.02 (0.59-1.77) 
15000-19999 0.15 (0.12-0.18)  0.50 (0.34-0.73)  0.41 (0.26-0.63) 0.35 (0.25-0.50)  0.88 (0.49-1.57)  1.00 (0.51-1.96) 
≥20000 0.18 (0.15-0.22)  0.61 (0.41-0.89)  0.49 (0.31-0.77) 0.18 (0.06-0.55)  0.29 (0.08-1.06)  0.34 (0.09-1.27) 
Rate of expansion (patients/month)          
<25 1.0 (ref)   1.0 (ref) 1.0 (ref) 1.0 (ref)    1.0 (ref) 1.0 (ref) 
25-59 0.64 (0.59-0.69)   0.93 (0.83-1.04) 0.93 (0.83-1.05) 0.74 (0.65-0.84)   0.89 (0.75-1.05) 0.93 (0.78-1.10) 
60-89 0.43 (0.40-0.47)   0.75 (0.64-0.87) 0.88 (0.74-1.04) 0.56 (0.49-0.65)   0.75 (0.61-0.93) 0.87 (0.68-1.12) 
90-124 0.37 (0.34-0.41)   0.75 (0.63-0.89) 1.06 (0.86-1.30) 0.52 (0.45-0.61)   0.84 (0.65-1.08) 1.02 (0.74-1.40) 
≥125 0.21 (0.20-0.24)   0.70 (0.58-0.85) 1.13 (0.87-1.48) 0.39  (0.32-0.47)   0.74 (0.54-1.02) 0.85 (0.55-1.31) 
Sex           
Female 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Male 1.61 (1.54-1.68) 1.29 (1.22-1.36) 1.30 (1.23-1.37) 1.29 (1.22-1.37) 1.30 (1.22-1.37) 1.77  (1.64-1.91) 1.57 (1.42-1.73) 1.57 (1.42-1.73) 1.57 (1.42-1.73) 1.57 (1.42-1.73) 
Age group (years)           
16-25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-34 1.07 (0.99-1.17) 1.11 (0.99-1.25) 1.10 (0.99-1.23) 1.11 (0.99-1.24) 1.10 (0.99-1.23) 0.94 (0.81-1.09) 0.85 (0.70-1.03) 0.85 (0.70-1.02) 0.85 (0.70-1.03) 0.85 (0.70-1.02) 
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35-44 1.16 (1.07-1.26) 1.18 (1.05-1.32) 1.16 (1.04-1.31) 1.17 (1.05-1.32) 1.17 (1.04-1.31) 1.10 (0.92-1.27) 0.99 (0.82-1.20) 0.99 (0.81-1.20) 0.99 (0.81-1.20) 0.99 (0.81-1.20) 
45+ 1.33 (1.22-1.46) 1.48 (1.31-1.67) 1.46 (1.29-1.65) 1.47 (1.31-1.66) 1.46 (1.29-1.65) 1.66 (1.42-1.95) 1.49 (1.22-1.82) 1.48 (1.21-1.81) 1.49 (1.22-1.82) 1.48 (1.21-1.82) 
Body Mass Index            
Underweight 3.65 (3.47-3.83) 2.58 (2.43-2.74) 2.60 (2.45-2.76) 2.58 (2.43-2.74) 2.59 (2.44-2.75) 1.67 (1.54-1.82) 1.57 (1.42-1.73) 1.57 (1.42-1.74) 1.56 (1.31-1.73) 1.56 (1.41-1.73) 
Normal 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Overweight 0.59 (0.50-0.69) 0.75 (0.62-0.90) 0.74 (0.61-0.90) 0.75 (0.62-0.90) 0.74 (0.61-0.90) 0.85 (0.69-1.03) 1.01 (0.80-1.27) 1.01 (0.80-1.27) 1.01 (0.80-1.28) 1.01 (0.80-1.28) 
Obese 0.88 (0.67-1.17) 1.23 (0.90-1.69) 1.22 (0.88-1.67) 1.24 (0.90-1.71) 1.22 (0.89-1.68) 0.93 (0.62-1.39) 0.76 (0.43-1.34) 0.76 (0.43-1.34) 0.77 (0.43-1.36) 0.76 (0.43-1.35) 
CD4 cell count (cells/μL)          
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-49 0.61 (0.57-0.66) 0.71 (0.65-0.78) 0.71 (0.65-0.78) 0.71 (0.65-0.78) 0.71 (0.65-0.78) 0.93 (0.78-1.10) 0.98 (0.82-1.18) 0.98 (0.81-1.18) 0.98 (0.82-1.18) 0.98 (0.81-1.18) 
50-99 0.39 (0.36-0.42) 0.52 (0.48-0.56) 0.52 (0.48-0.56) 0.52 (0.48-0.560 0.52 (0.48-0.56) 0.86 (0.72-1.00) 1.00 (0.85-1.18) 1.00 (0.85-1.18) 1.00 (0.85-1.18) 1.00 (0.84-1.18) 
100-149 0.26 (0.24-0.28) 0.41 (0.37-0.45) 0.41 (0.37-0.45) 0.41 (0.37-0.45) 0.41 (0.37-0.45) 0.63 (0.54-0.75) 0.79 (0.66-0.95) 0.79 (0.66-0.95) 0.80 (0.67-0.95) 0.79 (0.66-0.95) 
150-199 0.19 (0.18-0.21) 0.35 (0.31-0.39) 0.35 (0.31-0.39) 0.35 (0.31-0.39) 0.35 (0.31-0.39) 0.65 (0.55-0.76) 0.89 (0.74-1.07) 0.89 (0.74-1.06) 0.90 (0.75-1.07) 0.89 (0.74-1.06) 
200-349 0.15 (0.13-0.16) 0.29 (0.26-0.32) 0.29 (0.26-0.32) 0.29 (0.26-0.32) 0.29 (0.26-0.32) 0.52 (0.44-0.61) 0.74 (0.62-0.89) 0.74 (0.62-0.88) 0.75 (0.62-0.89)  0.74 (0.62-0.89) 
≥350 0.24 (0.21-0.28) 0.42 (0.36-0.49) 0.43 (0.36-0.50) 0.42 (0.36-0.49) 0.42 (0.36-0.49) 0.78 (0.60-1.03) 0.98 (0.72-1.33) 0.98 (0.72-1.34) 0.98 (0.72-1.33) 0.98 (0.72-1.33) 
Clinical stage           
1 and 2 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
3 2.60 (2.42-2.79 1.65 (1.51-1.80) 1.61 (1.47-1.76) 1.54 (1.50-1.79) 1.61 (1.47-1.76) 1.54 (1.38-1.73) 1.20 (1.05-1.38) 1.19 (1.04-1.37) 1.19 (1.04-1.37) 1.19 (1.03-1.36) 
4 5.70 (5.31-6.11) 2.73 (0.48-2.99) 2.65 (2.41-2.91) 2.69 (2.45-2.96) 2.65 (2.41-2.92) 2.26 (2.01-2.53) 1.54 (1.32-1.79) 1.51 (1.30-1.76) 1.52 (1.31-1.76) 1.51 (1.30-1.75) 
* All models accounted for site heterogeneity using random effects. Model 1 – demographics and baseline variables, Model 2 - Model 1 + programme size, Model 3 – Model 1 + rate of expansion, Model 4 – 
Model 1 + programme size and rate of expansion 
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Table 4: Cox proportional hazards estimates of LTFU by baseline characteristics and year of ART initiation, adjusted by cohort. * 
 0-12 months 12-72 months 
 Univariate 
 
HR (95% CI) 
Model 1 
(n=94 571) 
HR (95% CI) 
Model 2 
(n=94 571) 
HR (95% CI) 
Model 3 
(n=94 571) 
HR (95% CI) 
Model 4 
(n=94 571) 
HR (95% CI) 
Univariate 
 
HR (95% CI) 
Model 1 
(n=62 080) 
HR (95% CI) 
Model 2 
(n=62 080) 
HR (95% CI) 
Model 3 
(n=62 080) 
HR (95% CI) 
Model 4 
(n=62 080) 
HR (95% CI) 
Year of ART initiation           
≤2003 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
2004 1.62 (1.40-1.88) 1.52 (1.22-1.90) 1.06 (0.81-1.39) 1.36 (1.08-1.72) 1.09 (0.83-1.43) 1.31 (1.16-1.49) 1.19 (1.02-1.40) 1.03 (0.84-1.27) 1.09 (0.92-1.29) 1.04 (0.84-1.28) 
2005 1.69 (1.46-1.95) 1.99 (1.61-2.45) 1.34 (1.03-1.76) 1.74 (1.39-2.18) 1.37 (1.04-1.80) 1.19 (1.05-1.35) 1.20 (1.03-1.40) 1.03 (0.83-1.28) 1.00 (0.85-1.19) 0.94 (0.76-1.17) 
2006 1.62 (1.41-1.86) 2.18 (1.79-2.66) 1.54 (1.19-1.98) 1.80 (1.43-2.26) 1.43 (1.09-1.88) 1.47 (1.31-1.66) 1.67 (1.44-1.93) 1.45 (1.18-1.80) 1.27 (1.07-1.51) 1.17 (0.94-1.46) 
2007 2.04 (1.78-2.34) 3.25 (2.68-3.93) 2.25 (1.71-2.96) 2.60 (2.07-3.26) 2.19 (1.64-2.93) 1.82 (1.62-2.05) 2.37 (2.05-2.74) 2.19 (1.72-2.80) 1.76 (1.47-2.11) 1.83 (0.94-1.46) 
2008 2.26 (1.98-2.59) 3.58 (2.95-4.33) 2.43 (1.83-3.21) 2.66 (2.10-3.35) 2.31 (1.72-3.09) 2.44 (2.15-2.75) 3.30 (2.83-3.84) 3.02 (2.34-3.89) 2.33 (1.92-2.83) 2.48 (1.91-3.23) 
2009 2.14 (1.87-2.45) 3.58 (2.95-4.34) 2.37 (1.77-3.16) 2.52 (2.00-3.19) 2.14 (1.58-2.89) 3.60 (3.16-4.10) 4.71 (4.01-5.53) 4.54 (3.46-5.95) 3.26 (2.65-4.01) 3.58 (2.70-4.75) 
2010 2.99 (2.62-3.42) 5.46 (4.51-6.61) 3.52 (2.62-4.72) 3.74 (2.96-4.73) 3.29 (2.42-4.46) 6.50 (5.45-7.76) 8.47 (6.92-10.53) 8.50 (6.18-11.68) 5.94 (4.62-7.46) 6.86 (4.94-9.53) 
2011 3.64 (3.15-4.21) 6.17 (5.03-7.56) 3.61 (2.65-4.92) 4.06 (3.17-5.19) 3.51 (2.55-4.83) - - - - - 
Programme size (patients)          
<500 1.0 (ref)  1.0 (ref)  1.0 (ref) 1.0 (ref)  1.0 (ref)  1.0 (ref) 
500-999 1.71 (1.29-2.26)  2.01 (1.32-3.06)  1.86 (1.23-2.82) 1.64 (1.34-2.00)  1.45 (1.13-1.85)  1.40 (1.09-1.79) 
1000-2499 3.02 (2.33-3.92)  2.66 (1.75-4.05)  2.36 (1.55-3.58) 2.35 (1.94-2.86)  1.55 (1.19-2.02)  1.44 (1.10-1.88) 
2500-4999 3.29 (2.54-4.27)  2.80 (1.81-4.32)  2.29 (1.48-3.55) 2.66 (2.19-3.22)  1.64 (1.23-2.18)  1.34 (1.00-1.80) 
5000-7499 4.36 (3.36-5.67)  2.54 (1.61-4.00)  1.97 (1.24-3.10) 3.80 (3.11-4.65)  1.39 (1.00-1.92)  1.03 (0.74-1.43) 
7500 – 9999 4.60 (3.53-5.99)  2.72 (1.72-4.32)  1.67 (1.04-2.69) 5.47 (4.42-6.77)  1.44 (1.02-2.03)  0.83 (0.57-1.20) 
10000-14999 6.17 (4.73-8.04)  4.07 (2.53-6.53)  2.02 (1.22-3.34) 4.06 (3.22-5.12)  1.34 (0.90-1.99)  0.83 (0.54-1.27) 
15000-19999 5.97 (4.49-7.93)  4.52 (2.73-7.47)  2.27 (1.34-3.87) 4.89 (3.69-6.48)  1.11 (0.71-1.74)  0.74 (0.46-1.19) 
≥20000 7.35 (5.55-9.73)  3.66 (2.20-6.10)  1.77 (1.04-3.04) 7.03 (4.30-11.48)  0.81 (0.42-1.57)  0.53 (0.27-1.04) 
Rate of expansion (patients/month)          
<25 1.0 (ref)   1.0 (ref) 1.0 (ref) 1.0 (ref)    1.0 (ref) 1.0 (ref) 
25-59 1.57 (1.41-1.75)   1.36 (1.16-1.60) 1.26 (1.07-1.49) 1.48 (1.33-1.64)   1.24 (1.08-1.41) 1.22 (1.06-1.39) 
60-89 1.94 (1.73-2.18)   1.39 (1.14-1.69) 1.36 (1.10-1.67) 1.96 (1.75-2.18)   1.43 (1.21-1.68) 1.56 (1.31-1.85) 
90-124 2.16 (1.92-2.4)   1.61 (1.31-1.98) 1.70 (1.35-2.14) 2.79 (2.48-3.14)   1.86 (1.55-2.23) 2.22 (1.81-2.72) 
≥125 3.09 (2.74-3.48)   2.21 (1.78-2.75) 2.31 (1.78-3.01) 3.72 (3.25-4.27)   1.65 (1.33-2.05) 2.29 (1.76-2.99) 
Sex           
Female 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Male 1.31 (1.27-1.36) 1.26 (1.20-1.32) 1.26 (1.20-1.32) 1.25 (1.19-1.31) 1.25 (1.2-1.31) 1.16 (1.11-1.21) 1.21 (1.14-1.28) 1.21 (1.15-1.28) 1.21 (1.14-1.28) 1.21 (1.15-1.29) 
Age group (years)           
16-25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-34 0.72 (0.69-0.76) 0.72 (0.67-0.77) 0.72 (0.67-0.77) 0.72 (0.67-0.77) 0.72 (0.67-0.77) 0.63 (0.59-0.67) 0.66 (0.60-0.72) 0.66 (0.60-0.72) 0.66 (0.60-0.72) 0.66 (0.60-0.72) 
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35-44 0.60 (0.57-0.64) 0.60 (0.55-0.64) 0.59 (0.55-0.64) 0.60 (0.55-0.64) 0.59 (0.55-0.64) 0.50 (0.47-0.54) 0.51 (0.46-0.56) 0.51 (0.46-0.56) 0.51 (0.46-0.56) 0.51 (0.46-0.56) 
45+ 0.60 (0.56-0.64) 0.58 (0.53-0.63) 0.58 (0.53-0.63) 0.58 (0.53-0.63) 0.58 (0.53-0.63) 0.51 (0.47-0.56) 0.49 (0.44-0.54) 0.49 (0.44-0.54) 0.49 (0.44-0.54) 0.48 (0.44-0.54) 
Body Mass Index            
Underweight 1.70 (1.63-1.77) 1.53 (1.45-1.60) 1.52 (1.45-1.59) 1.52 (1.45-1.60) 1.52 (1.45-1.60) 1.12 (1.07-1.18) 1.06 (1.00-1.13) 1.07 (1.00-1.13) 1.06 (1.00-1.13) 1.07 (1.00-1.13) 
Normal 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Overweight 0.91 (0.83-0.99) 0.93 (0.84-1.03) 0.93 (0.84-1.03) 0.93 (0.84-1.03) 0.93 (0.83-1.03) 0.99 (0.90-1.109) 1.08 (0.96-1.20) 1.08 (0.96-1.20) 1.08 (0.97-1.21) 1.08 (0.97-1.21) 
Obese 1.21 (0.96-1.31) 1.14 (0.94-1.39) 1.14 (0.94-1.39) 1.14 (0.94-1.39) 1.14 (0.93-1.38) 0.86 (0.70-1.07) 0.98 (0.77-1.25) 0.98 (0.76-1.25) 0.98 (0.76-1.25) 0.97 (0.76-1.25) 
CD4 cell count (cells/μL)          
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-49 0.81 (0.74-0.87) 0.89 (0.82-0.97) 0.88 (0.81-0.97) 0.89 (0.81-0.97) 0.89 (0.81-0.97) 0.93 (0.84-1.04) 0.98 (0.8-1.10) 0.99 (0.88-1.11) 0.98 (0.88-1.10) 0.99 (0.88-1.11) 
50-99 0.61 (0.57-0.66) 0.73 (0.67-0.79) 0.72 (0.66-0.78) 0.72 (0.67-0.78) 0.72 (0.66-0.78) 0.87 (0.79-0.95) 0.95 (0.85-1.05) 0.95 (0.86-1.05) 0.94 (0.85-1.04) 0.95 (0.85-1.05) 
100-149 0.56 (0.52-0.60) 0.70 (0.64-0.76) 0.69 (0.66-0.78) 0.69 (0.64-0.75) 0.69 (0.64-0.75) 0.85 (0.77-0.94) 0.97 (0.88-1.08) 0.98 (0.88-1.08) 0.97 (0.87-1.07) 0.97 (0.88-1.08) 
150-199 0.47 (0.44-0.51) 0.60 (0.55-0.66) 0.60 (0.64-0.75) 0.60 (0.55-0.65) 0.59 (0.55-0.65) 0.88 (0.80-0.97) 0.98 (0.88-1.09) 0.98 (0.89-1.09) 0.97 (0.88-1.08) 0.98 (0.88-1.09) 
200-349 0.51 (0.48-0.55) 0.60 (0.56-0.66) 0.60 (0.55-0.65) 0.60 (0.56-0.65) 0.60 (0.55-0.65) 0.92 (0.84-1.01) 0.91 (0.82-1.01) 0.92 (0.83-1.02) 0.91 (0.82-1.01) 0.92 (0.83-1.02) 
≥350 0.78 (0.71-0.87) 0.76 (0.68-086) 0.77 (0.68-0.86) 0.77 (0.68-0.86) 0.77 (0.68-0.86) 1.13 (0.96-1.32) 1.07 (0.91-1.27) 1.09 (0.92-1.29) 1.05 (0.89-1.25) 1.05 (0.89-1.25) 
Clinical stage           
1 and 2 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
3 1.10 (1.05-1.14) 1.15 (1.09-1.22) 1.17 (1.11-1.24) 1.17 (1.11-1.24) 1.17 (1.10-1.23) 1.05 (0.99-1.11) 1.21 (1.13-1.30) 1.21 (1.13-1.29) 1.20 (1.12-1.28) 1.18 (1.10-1.27) 
4 1.51 (1.44-1.59) 1.52 (1.42-1.62) 1.55 (1.45-1.65) 1.56 (1.46-1.67) 1.56 (1.46-1.66) 1.11 (1.04-1.18) 1.29 (1.19-1.40) 1.29 (1.19-1.40) 1.29 (1.19-1.40) 1.28 (1.18-1.39) 
* All models accounted for site heterogeneity using random effects. Model 1 – demographics and baseline variables, Model 2 - Model 1 + programme size, Model 3 – Model 1 + rate of expansion, Model 4 – 
Model 1 + programme size and rate of expansio
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